Decamethrin pharma grade API, the (S)-α-cyano-3-phenoxybenzyl (1R,3R)-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropanecarboxylate ester, exhibits an aqueous solubility below 0.01 mg/L at 25°C and a log P above 4.5 based on publicly available physical chemistry data for the pyrethroid. For oral tablet, capsule, granule, and injectable presentation development, these two properties impose common constraints: particle size reduction or inclusion complexation before aqueous granulation, avoidance of alkaline hydrolysis during processing, and selection of non-aqueous or pH-controlled vehicles for sterile liquid forms. The molecule does not contain an ionizable group that would provide pH-dependent aqueous solubility in the gastrointestinal pH range, so solubility enhancement cannot rely on pH adjustment alone. Because the dosage forms listed in the application scope include tablet, capsule, granule, injection, oral, and injectable presentations, the downstream scenarios below are organized by unit operation rather than by therapeutic claim. No clinical efficacy endpoint is implied; the content addresses processability, compliance, and stability boundaries only. Unless otherwise indicated, the stated process ranges are starting points derived from standard pharmaceutical unit operation practice, not from a compendial decamethrin monograph; published data for decamethrin in each exact matrix are limited.

Wet Granulation Integrity When the API Is a Low-Solubility Pyrethroid Ester

The wet granulation route for decamethrin tablets is selected only when direct compression cannot accommodate the required dose and blend uniformity, typically when the API is present at ≤10% w/w. The API is first jet-milled to a D90 no greater than 10 µm, with particle size confirmed by laser diffraction under USP <429>. If the drug load is below 1% w/w, a geometric dilution with microcrystalline cellulose is performed before main blending. The milled API is pre-blended with microcrystalline cellulose, lactose monohydrate, and croscarmellose sodium in a twin-shell blender for 10–15 min at 12–18 rpm; this pre-blend is then transferred to a high-shear granulator equipped with an impeller and chopper. The binder solution contains 3–5% w/w povidone K30 or 2–4% w/w hypromellose 5 cP dissolved in purified water that has been adjusted to pH 3.5–5.5 with citric acid. The acidic granulation fluid is used because published pyrethroid degradation data show rapid ester hydrolysis in neutral-to-alkaline media; final granulation fluid pH is recorded with a calibrated pH meter under USP <791>. Impeller speed is set at 200–300 rpm and chopper speed at 1500–2500 rpm for a 10 L bowl; granulation fluid is added at 5–10 g/min per kg of dry blend, and wet massing is continued for 1–2 min after the visual end point. Wet granules are passed through a 1.0 mm screen and dried in a fluid-bed dryer with inlet air temperature 55–65°C and product temperature not exceeding 40°C; final loss on drying is not more than 1.5% by USP <921>. Dried granules are milled through a 0.8 mm screen and blended with magnesium stearate at 0.5% w/w for 3–5 min; over-lubrication is avoided because hydrophobic magnesium stearate can retard dissolution of a low-solubility API. Compression is executed on a rotary tablet press with pre-compression force 1–3 kN and main compression force 8–15 kN for a 250 mg round tooling set; tablet breaking force is measured under USP <1217> and adjusted to a target tensile strength rather than a fixed hardness value. Friability is controlled by USP <1216> to not more than 1.0% after 100 rotations. Dissolution testing uses USP <711> Apparatus 2 at 75 rpm in 900 mL of 0.1 N HCl containing 0.1% sodium lauryl sulfate; neat aqueous media do not provide sink conditions for an API with aqueous solubility below 0.01 mg/L. Content uniformity is assessed by USP <905> with stratified sampling at beginning, middle, and end of compression. Published data for decamethrin in this exact wet granulated tablet matrix are limited; the surfactant level in the dissolution medium is justified by solubility measurement in the medium rather than by product-specific compendial precedent.

In hard capsule development, exclusion of aqueous granulation is the primary means of limiting hydrolytic degradation of the ester. Roller compaction is therefore evaluated before wet granulation when the decamethrin pharma grade API is filled into hard gelatin or HPMC capsules. The API is pre-blended with microcrystalline cellulose and lactose monohydrate using a geometric dilution sequence if the drug load is ≤1% w/w; the pre-blend is passed through a 0.5 mm screen and mixed in a diffusion blender for 15–20 min to achieve blend uniformity before dry granulation. Roller compaction is performed on a fixed-gap roller compactor with roll pressure 4–8 MPa, roll gap 1.0–2.0 mm, and roll speed 5–10 rpm; roll surface temperature is monitored and maintained below 40°C because published melting point data for deltamethrin fall near 98–101°C. Compacted ribbons are milled through an oscillating mill fitted with a 0.8–1.2 mm screen; granules are collected and blended with croscarmellose sodium and magnesium stearate. The final blend is filled into hard capsules using a dosator or tamping-pin capsule filling machine to a target weight of 200–400 mg, with fill weight monitored by in-process weight checks at 15-minute intervals. Granule moisture is controlled to not more than 1.0% by USP <921> because residual water can participate in ester hydrolysis during storage. Hard gelatin capsule shells contain 13–16% moisture and can transfer water to the dry granule; HPMC capsule shells with lower moisture content may be selected when accelerated stability data show degradation. Blend uniformity and content uniformity are tested by USP <905>, and particle size of the final granulation is checked by sieve analysis under USP <786>. Capsule disintegration is evaluated using USP <701>; if dissolution is required, the same surfactant-containing medium described for tablets is used under USP <711>. Ribbon density is recorded as a process indicator, but the acceptance range is established during development because published data for decamethrin roller compaction behavior are limited.

Fluid-Bed Granule Drying and the Hydrolytic Degradation Boundary

Top-spray fluid-bed granulation is configured with a standard top-spray nozzle positioned above the fluidized powder bed for immediate-release decamethrin granules; a Wurster insert is not required unless a controlled-release or drug-layered granule is specified. The API is pre-milled to a D90 no greater than 10 µm and pre-blended with mannitol, microcrystalline cellulose, and povidone K30. The binder solution is purified water adjusted to pH 3.5–5.5 with citric acid; the acidic pH is selected to reduce the hydrolytic degradation boundary known from published pyrethroid stability data. Inlet air temperature is set at 50–60°C, product temperature is maintained at 30–35°C, spray rate is 5–15 g/min per kg of bed weight, atomization air pressure is 1.0–2.0 bar, and inlet airflow is 20–30 m³/h per kg of dry powder. The filter bag is shaken intermittently every 30–60 seconds to return fines to the bed and prevent build-up of unagglomerated API on the filter. Drying continues after spraying until product temperature reaches 35–38°C and loss on drying by USP <921> is not more than 1.5%. The dried granules are screened through a 1.25 mm sieve; the target particle size is a d50 of 150–300 µm with fines below 75 µm limited to less than 15% w/w to prevent segregation in sachet filling. Bulk density and tapped density are measured under USP <616>; the target Hausner ratio is not more than 1.25 to ensure uniform sachet fill weights on a vertical form-fill-seal machine. Sachet filling is performed under 25°C/60% RH only if stability data confirm that open processing time does not increase moisture beyond the 1.5% limit; otherwise relative humidity is reduced to 35–40%. The finished granule is packaged in a foil laminate with a moisture vapor transmission rate below 0.1 g/m²/24 h; published data for decamethrin in this exact fluid-bed granule matrix are limited, so this moisture barrier requirement is based on the known hydrolysis liability of the ester rather than product-specific stability.

What Limits Terminal Sterilization for an Injectable Decamethrin Solution?

Terminal sterilization is assessed first for injectable decamethrin because Ph. Eur. 5.1.1 and USP <1229> direct manufacturers to prefer terminal sterilization whenever product quality permits. Aqueous solubility below 0.01 mg/L prevents a simple aqueous solution at typical therapeutic concentrations; formulation development therefore moves to co-solvent or cyclodextrin systems. Co-solvent screening includes propylene glycol, polyethylene glycol 400, and ethanol in water, with the final ratio determined by solubility measurement in the selected vehicle and by osmolality testing under USP <785>. Sulfobutyl ether β-cyclodextrin is evaluated as an inclusion complexation agent because the lipophilic cavity can accommodate the pyrethroid ester; however, published data for the complexation stoichiometry and binding constant of decamethrin with SBE-β-CD in pharmaceutical-grade water-for-injection are limited. Any solution containing free water is exposed to moist-heat terminal sterilization only after hydrolytic degradation kinetics are experimentally established at 121°C for 15 min; if assay loss exceeds 0.5% per sterilization cycle or if related substances exceed the acceptance limit, terminal moist-heat sterilization is considered incompatible with the API. In that case, aseptic filtration through a 0.22 µm PVDF membrane is used in an ISO 14644-1 Class 5 environment, with filter integrity tested by bubble point or diffusive flow under ASTM F838-20 before and after filling. Sterility is confirmed by direct inoculation or membrane filtration under USP <71>, and bacterial endotoxins are tested by USP <85> with the limit calculated from the maximum human dose and the endotoxin limit expression given in the chapter. Visible particulates are inspected under USP <790>, and subvisible particulates are measured with light obscuration under USP <788>; for a small-volume injection, the limit is not more than 6000 particles ≥10 µm and not more than 600 particles ≥25 µm per container. The selected container closure system is validated for protection against light because pyrethroids are photolabile; amber Type I glass vials with halogenated butyl stoppers are evaluated under ICH photostability conditions. The table below summarizes the quality attribute and test method matrix for this sterile presentation.

Injectable suspension development for decamethrin is driven by the fact that the API is practically insoluble in water; a suspension can present a higher dose per unit volume than a co-solvent solution but introduces physical stability and syringeability constraints. The drug is wet-milled or high-pressure homogenized to a D90 of 1–5 µm in a vehicle containing water for injection, polysorbate 20 or polysorbate 80 as wetting agent, and a suspending agent such as sodium carboxymethylcellulose or poloxamer 188. Milling temperature is kept below 40°C by jacketed cooling because the ester is thermally and hydrolytically labile; the jacket inlet temperature is set at 10–15°C. The particle size distribution span, defined as (D90-D10)/D50, is controlled to below 2.0 to reduce settling rate differences between fine and coarse fractions. Viscosity is measured with a rotational rheometer at 25°C; the target apparent viscosity at a shear rate of 10 s^-1 is 10–50 mPa·s to balance resuspendability against syringeability through a 21-gauge needle. Zeta potential is measured by electrophoretic light scattering; an absolute value above 30 mV is used as a screening target for electrostatic stabilization, but published data for decamethrin suspension zeta potential are limited. Sedimentation volume and redispersibility are tested by a standardized manual shaking test after storage at 2–8°C and 25°C/60% RH; if caking occurs, the suspending agent type or concentration is changed. Terminal sterilization of the suspension by gamma irradiation may be evaluated only if assay, related substances, and particle size remain within specification; if radiation-induced degradation exceeds 0.5%, aseptic processing is required. Single-dose preservative-free vials are used unless multi-dose use is justified; if a multi-dose presentation is required, benzyl alcohol at 0.9% w/v is evaluated as a preservative, with its level controlled under USP <51> and residual solvent limits under ICH Q3C. The finished suspension is tested for sterility by USP <71>, endotoxins by USP <85>, and particulate matter by USP <788>.

If Lyophilization Is Selected for a Hydrophobic API, Cake Collapse Must Be Controlled

Lyophilization is considered only after liquid and suspension presentations have been screened against the API’s hydrolysis liability and solubility boundary. Because decamethrin is practically insoluble in pure water, a freeze-drying solvent system may contain 20–30% w/w tert-butanol in water to dissolve the API and provide a crystalline or amorphous cake after sublimation. Tert-butanol is a Class 2 residual solvent under ICH Q3C; its limit is set on the basis of the permitted daily exposure, and the freeze-drying cycle is designed to reduce the residual level below that limit. Freezing is performed on a lyophilizer with shelf temperature ramped to -45°C at 0.5–1.0°C/min, followed by annealing at -20°C for 2–4 h to promote tert-butanol crystallization and reduce cake collapse. Primary drying is conducted at a shelf temperature of -30°C to -20°C and chamber pressure 0.1 mbar for 24–36 h; the endpoint is determined by comparative pressure measurement or product temperature rise rather than time alone. Secondary drying is performed at 25°C and 0.05 mbar until residual moisture by USP <921> is below 0.5%. Cake appearance is inspected for collapse, meltback, and cracking; collapsed cake is a cause for batch rejection because it indicates loss of the intended porous structure and may affect reconstitution time. Reconstitution is evaluated using water for injection or a co-solvent vehicle; if reconstitution time exceeds 2 minutes with manual swirling, the formulation is modified with a bulking agent such as mannitol or glycine. Sterility is maintained by aseptic filtration of the pre-lyophilization solution through a 0.22 µm membrane under ISO 14644-1 Class 5, and the sealed vials are tested under USP <71> and USP <85>. Published data for decamethrin lyophilization under this exact solvent and cycle configuration are limited; the parameters above are starting points that require freeze-drying microscopy and differential scanning calorimetry to confirm the glass transition temperature of the maximally freeze-concentrated formulation.